Cagrilintide Dosing & Protocols — Research Reference

Cagrilintide is a long-acting amylin analogue studied alone and in combination with GLP-1 receptor agonists (most notably semaglutide, as the CagriSema combination). Its mechanism is complementary — not redundant — to GLP-1 agonism.

Reconstitution for Research

Cagrilintide is typically supplied lyophilized in 5 mg or 10 mg vials. A 2 mL bacteriostatic-water reconstitution of a 10 mg vial yields 5 mg/mL; 10 IU at that concentration delivers 500 mcg. Refrigerate at 2–8 °C and use within the COA's documented window.

Reference Dose Ranges in Published Research

| Phase | Typical range | Notes | |---|---|---| | Titration weeks 1–4 | 0.16–0.3 mg per week | Universal slow start to manage nausea | | Standard maintenance | 1.2–2.4 mg per week | Most cited research tier | | High-dose pharmacology | 4.5 mg per week | Used in dose-finding and CagriSema research |

Scheduling

Once-weekly subcutaneous injection. The titration ladder typically doubles the dose every 2–4 weeks until target maintenance is reached. Cagrilintide alone produces a smaller GI-adverse-event burden than GLP-1 agonists; combination protocols (CagriSema) follow GLP-1 titration cadence.

Co-Administration with Semaglutide (CagriSema)

The published CagriSema research uses fixed-ratio dosing — typically equal milligram amounts of cagrilintide and semaglutide injected separately on the same day. The amylin arm contributes additional satiety signalling through the area postrema (different brainstem nuclei than GLP-1), producing additive weight-research endpoints in published trials.

Amylin-Receptor Considerations

Cagrilintide is a non-selective amylin/calcitonin family agonist with primary activity at AMY1, AMY2, and AMY3 receptor complexes (calcitonin receptor + RAMP1/2/3). The acylated C16 fatty-acid chain produces albumin binding and the weekly half-life.

Quality and Identity Verification

LC-MS confirmation of molecular weight and HPLC purity ≥98% are the standard acceptance criteria.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.

References

1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160–2172.
2. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720–730.
3. Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183–11194.